# Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

> **NCT04941937** · PHASE2 · UNKNOWN · sponsor: **Juan Du** · enrollment: 90 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Thalidomide
- **DRUG:** Lenalidomide
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04941937
- **Lead sponsor:** Juan Du
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-27
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04941937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04941937, "Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04941937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*